Lig4 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| DNA Ligase 4 (LIG4) | |
|---|---|
| Gene Symbol | LIG4 |
| Full Name | DNA Ligase 4 |
| Chromosome | 13q33.3 |
| NCBI Gene ID | 3981 |
| OMIM | 601837 |
| Ensembl ID | ENSG00000174444 |
| UniProt ID | P18859 |
| Associated Diseases | LIG4 syndrome, Cancer, Neurodegeneration |
DNA Ligase 4 (LIG4) is a critical enzyme in the non-homologous end joining (NHEJ) pathway of DNA double-strand break repair. It plays an essential role in maintaining genomic stability, particularly in neurons which are highly metabolically active cells with long lifespans and limited regenerative capacity. LIG4 deficiency leads to LIG4 syndrome, a rare autosomal recessive disorder characterized by immunodeficiency, microcephaly, growth retardation, and predisposition to malignancies. Research has increasingly implicated DNA repair defects, including NHEJ dysfunction, in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
LIG4 is the ATP-dependent DNA ligase that catalyzes the final ligation step in the classical NHEJ (c-NHEJ) pathway, which is the predominant mechanism for repairing DNA double-strand breaks (DSBs) in mammalian cells. The NHEJ pathway operates throughout the cell cycle and does not require sequence homology, making it essential for genomic stability.
The LIG4 protein forms a stable heterodimer with XRCC4, which is essential for its stability and function. This LIG4-XRCC4 complex is recruited to DNA break sites by the Ku70/Ku80 heterodimer, which binds to DNA ends and recruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Additional processing enzymes, including Artemis and polymerase mu/lambda, prepare the DNA ends for ligation. LIG4-XRCC4 then catalyzes the formation of phosphodiester bonds to reconnect the broken DNA strands.
LIG4 is absolutely essential for V(D)J recombination, the process that generates antibody and T-cell receptor diversity in the developing immune system. During V(D)J recombination, RAG1/2 endonuclease creates DNA double-strand breaks at recombination signal sequences, and the NHEJ machinery, including LIG4, joins these broken ends to form functional immune receptor genes. Mutations in LIG4 cause severe combined immunodeficiency (SCID) due to defective V(D)J recombination.
Neurons are post-mitotic cells that must survive for decades while maintaining genomic integrity. The NHEJ pathway, with LIG4 as a core component, is particularly important for:
LIG4 syndrome (OMIM #606593) is a rare autosomal recessive disorder caused by biallelic mutations in the LIG4 gene. Clinical features include:
The phenotype resembles ataxia-telangiectasia but with milder neurological features. Fibroblasts from LIG4 syndrome patients show profound defects in NHEJ repair and extreme sensitivity to ionizing radiation.
Accumulating evidence links NHEJ dysfunction to neurodegenerative diseases:
Alzheimer's Disease (AD):
Parkinson's Disease (PD):
Amyotrophic Lateral Sclerosis (ALS):
LIG4 polymorphisms and expression changes have been associated with various cancers. While complete LIG4 deficiency causes immunodeficiency, partial defects may allow survival of damaged cells and tumor progression. LIG4 expression is often upregulated in cancers as a survival mechanism to cope with genotoxic stress from rapid proliferation.
LIG4 is ubiquitously expressed in all tissues, including high expression in:
In the brain, LIG4 is expressed in:
Expression is generally higher in proliferating cells but remains essential in post-mitotic neurons for DNA repair.
Given the role of DNA damage in neurodegeneration, enhancing NHEJ activity is being explored as a therapeutic strategy:
LIG4 inhibition is being explored as a therapeutic target in cancer:
The study of Lig4 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.